Cancer
(asked on 29th October 2014) - View Source
Question to the Department of Health and Social Care:
To ask Her Majesty’s Government what assessment they have made of emerging immuno-oncology treatments and their impact on patient survival and the design of National Health Service cancer services.
This question was answered on 17th November 2014
The National Institute for Health and Care Excellence (NICE) provides advice to the National Health Service on the clinical and cost-effectiveness of drugs and treatments. We understand that at least one immuno-oncology treatment, sipuleucel-T for prostate cancer, is currently being appraised by NICE. Further information is available at:
www.nice.org.uk/guidance/indevelopment/GID-TAG346